SEARCH

SEARCH BY CITATION

References

  • 1
    Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119: 10821.
  • 2
    Committee for Proprietary Medicinal Products (CPMP). Points to consider on clinical investigation of medicinal products for prophylaxis of intra- and postoperative venous thromboembolic risk. EMEA website, accessed 29 June 2000. available at: http://www.eudra.org/emea.html.
  • 3
    Committee for Proprietary Medicinal Products (CPMP). Notes for guidance on clinical investigation of medicinal products for the treatment of venous thromboembolic disease. EMEA website, accessed 16 December 1999. Available at: http://www.eudra.org/emea.html.
  • 4
    Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment. Chest 2004; 126: S287310.
  • 5
    Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345: 1659.
  • 6
    Eriksson H, Wåhlander K, Gustafsson D, Welin L, Frison L, Schulman S. A randomised, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 417.